Concerning additional alterations, EGFR/ALK/BRAF co-mutations are rare in KRAS-mutant lung adenocarcinoma; concomitant mutations in onco-suppressor genes, especially TP53, STK11 and KEAP1, are more often found (11, 14, 46, 47). This evidence concerns the gene KRAS and lung adenocarcinoma.